166 results on '"Lebbé, Céleste"'
Search Results
2. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
3. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
4. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
5. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
6. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II
7. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
8. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
9. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
10. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
11. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
12. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
13. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023
14. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023
15. Hyperprogression in advanced melanoma is not restricted to immunotherapy
16. Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
17. Biomarqueurs prédictifs de la réponse à l’immunothérapie dans les mélanomes
18. Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease
19. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
20. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort
21. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review
22. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors
23. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
24. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
25. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
26. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
27. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
28. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
29. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort
30. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
31. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
32. Un exemple de réorganisation dans le fonctionnement d’un Centre d’investigations cliniques en période de confinement national suite à la pandémie COVID-19
33. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
34. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
35. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
36. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
37. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
38. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
39. Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal
40. Deep cutaneous fungal infections in solid-organ transplant recipients
41. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
42. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
43. Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
44. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019
45. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
46. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
47. Line-field confocal optical coherence tomography (LC-OCT) features of a melanotic macule of the lip
48. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
49. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
50. Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.